Characteristics | N (107) | Progression Free Survival | Overall Survival | |||||
---|---|---|---|---|---|---|---|---|
 |  |  | HR | 95% CI | P | HR | 95% CI | p |
Sex | Females | 39 | 1 | Â | Â | 1 | Â | Â |
 | Males | 68 | 0.97 | 0.65-1.45 | 0.893 | 0.83 | 0.51-1.30 | 0.397 |
Age | ≤ 65 years | 60 | 1 |  |  | 1 |  |  |
 | >65 years | 47 | 0.78 | 0.51-1.15 | 0.197 | 0.94 | 0.61-1.44 | 0.782 |
ECOG PS | 0 | 83 | 1 | Â | Â | 1 | Â | Â |
 | 1-2 | 24 | 1.34 | 0.84-2.31 | 0.196 | 2.32 | 1.68-6.23 | 0.0004 |
Previous adjuvant CT | No | 75 | 1 | Â | Â | 1 | Â | Â |
 | Yes | 32 | 1.13 | 0.74-1.75 | 0.562 | 0.77 | 0.49-1.22 | 0.268 |
No. of metastatic sites | 1 | 57 | 1 | Â | Â | 1 | Â | Â |
 | >1 | 50 | 1.10 | 0.75-1.62 | 0.632 | 0.88 | 0.57-1.34 | 0.542 |
Liver-only metastases | No | 68 | 1 | Â | Â | 1 | Â | Â |
 | Yes | 39 | 0.81 | 0.54-1.19 | 0.270 | 0.97 | 0.63-1.51 | 0.901 |
High CEA level | No | 85 | 1 | Â | Â | 1 | Â | Â |
 | Yes | 22 | 1.45 | 0.91-2.68 | 0.109 | 1.91 | 1.22-4.36 | 0.010 |
-1498 | C/C | 25 | 1 | Â | Â | 1 | Â | Â |
 | C/T | 55 | 1.09 | 0.68-1.76 | 0.719 | 0.89 | 0.50-1.55 | 0.662 |
 | T/T | 27 | 0.89 | 0.50-1.54 | 0.653 | 0.73 | 0.36-1.39 | 0.311 |